Estimated reading time: 4 minutes Key Takeaways Revenue hit a record US$94 billion, beating consensus estimates. Double-digit iPhone growth and surging Services income shored up margins. Heavy spending on Apple Intelligence …
-
-
Estimated reading time: 4 minutes Key Takeaways Figma’s Nasdaq debut opened near $99 per share, nearly tripling its IPO price and valuing the company at roughly $59 billion. CEO Dylan Field’s …
-
Estimated reading time: 4 minutes Key Takeaways The Dow Jones Industrial Average slipped 0.7 %, erasing earlier gains as healthcare weakness overshadowed tech resilience. Intraday volatility featured a wide 616-point …
-
Estimated reading time: 7 minutes Key Takeaways 35 % one-day share price collapse following a modest revenue miss and reduced outlook. Management unveils a $150-$170 million restructuring targeting 20-25 % cost savings. Clear …
-
Estimated reading time: 6 minutes Key Takeaways Figma’s IPO catapulted its valuation and placed CEO Dylan Field on the cusp of multi-billionaire status. Field’s remuneration relies almost entirely on share-price …
-
Estimated reading time: 6 minutes Key Takeaways Nations are striking *last-minute* trade pacts to avoid looming tariff hikes. Tariff ceilings and **reciprocal tariffs** are central bargaining tools. Export quotas on …
-
Estimated reading time: 6 minutes Key Takeaways Shares of Figma tripled on debut, underlining intense demand for high-growth software names. Opening price eclipsed the US$33 offer, trading in the US$101–US$112 …
-
Estimated reading time: 5 minutes Key Takeaways Cocoa prices have surged 73% in five years, forcing confectioners to rethink pricing. Hershey’s portfolio diversity lets it keep 75% of SKUs under …
-
Estimated reading time: 4 minutes Key Takeaways Q2 profit beat Wall Street expectations, signalling robust demand. Revenue climbed, but the exact figure is pending the formal SEC filing. Shares slipped …
-
Estimated reading time: 4 minutes Key Takeaways *Healthcare losses dragged the* Dow Jones Industrial Average *lower while tech giants bucked the trend.* White House rhetoric on drug pricing spurred a …